(Q53352517)

13 May 2018

title

Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. (English)

1 reference

13 May 2018

0 references

0 references

0 references

1 reference

Maria Grazia De Simoni

6

1 reference

13 May 2018

Luigi Bergamaschini

object named as

Luigi Bergamaschini

1

0 references

author name string

Cesare Donarini

2

1 reference

13 May 2018

Emanuela Rossi

3

1 reference

13 May 2018

Ada De Luigi

4

1 reference

13 May 2018

Carlo Vergani

5

1 reference

13 May 2018

publication date

1 July 2002

1 reference

13 May 2018

published in

Neurobiology of Aging

1 reference

13 May 2018

volume

23

1 reference

13 May 2018

issue

4

1 reference

13 May 2018

page(s)

531-536

1 reference

13 May 2018

Inflammatory mechanisms in Alzheimer's disease: implications for therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Activation of the contact system in cerebrospinal fluid of patients with Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Evidence for genetic linkage of Alzheimer's disease to chromosome 10q

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Neuropathological stageing of Alzheimer-related changes

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Heparin binding and augmentation of C1 inhibitor activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

A postulated mechanism for heparin's potentiation of C1 inhibitor function

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Neuroglial-mediated immunoinflammatory responses in Alzheimer's disease: complement activation and therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

beta-Amyloid converts an acute phase injury response to chronic injury responses

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

The role of complement in Alzheimer's disease pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Alpha-synuclein and Parkinson's disease: selective neurodegenerative effect of alpha-synuclein fragment on dopaminergic neurons in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Mechanisms of beta-amyloid neurotoxicity: perspectives of pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Interaction of factor XII and high molecular weight kininogen with cytokeratin 1 and gC1qR of vascular endothelial cells and with aggregated Abeta protein of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

CSF and serum concentrations of albumin and IgG in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Elevated abeta42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AbetaPP metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Immunoglobulin-sulfated polysaccharide interactions. Binding of agaropectin and heparin by human IgG proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Susceptibility locus for Alzheimer's disease on chromosome 10.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Zinc-dependent activation of the plasma kinin-forming cascade by aggregated beta amyloid protein

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

In vitro evidence that beta-amyloid peptide 1-40 diffuses across the blood-brain barrier and affects its permeability.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Heparin in inflammation: potential therapeutic applications beyond anticoagulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Complement C1-inhibitor expression in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Complement. First of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Complement. Second of two parts

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

Hageman factor and its binding sites are present in senile plaques of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0197-4580%2802%2900003-9

7 January 2021

10.1016/S0197-4580(02)00003-9

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

12009502

1 reference

13 May 2018